SAB Biotherapeutics, Inc.
SABS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.
Other share classesSABSW
Q4 2025 vs. Q3 2025
How the institutions holding SAB Biotherapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 34 | 48 | +14 |
| Shares | 28.0M | 36.3M | +8.32M (+29.7%) |
| Value | $56.3M | $135.9M | +$79.6M (+141.3%) |
New holders (21)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Spruce Street Capital LP | 2,198,502 | $8.22M | 2.72% |
| Blackstone Group Inc. | 2,143,585 | $8.02M | 0.03% |
| Perceptive Advisors LLC | 803,210 | $3.00M | 0.06% |
| Propel Bio Management, LLC | 652,881 | $2.44M | 2.08% |
| Jefferies Financial Group Inc. | 580,328 | $2.17M | 0.02% |
| Balyasny Asset Management LLC | 475,439 | $1.78M | 0.00% |
| Millennium Management LLC | 324,090 | $1.21M | 0.00% |
| Ameriprise Financial Inc | 283,645 | $1.06M | 0.00% |
| Marshall Wace, LLP | 236,460 | $884.4K | 0.00% |
| Simplify Asset Management Inc. | 208,227 | $778.8K | 0.01% |
| StemPoint Capital LP | 146,558 | $548.1K | 0.09% |
| ExodusPoint Capital Management, LP | 86,113 | $322.1K | 0.00% |
| Omers Administration Corp | 42,000 | $157.1K | 0.00% |
| Qube Research & Technologies Ltd | 31,147 | $116.5K | 0.00% |
| Verition Fund Management LLC | 26,867 | $100.5K | 0.00% |
| Persistent Asset Partners Ltd | 19,790 | $74.0K | 0.04% |
| Colony Group, LLC | 19,201 | $71.8K | 0.00% |
| Citadel Advisors LLC | 17,650 | $66.0K | 0.00% |
| Fifth Lane Capital, LP | 15,000 | $56.1K | 0.07% |
| State Street Corp | 13,122 | $49.1K | 0.00% |
| State of Wyoming | 8,971 | $33.6K | 0.00% |
Sold out (7)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| BVF Inc | 932,697 | $1.87M |
| Sphera Funds Management Ltd. | 566,395 | $1.14M |
| Renaissance Technologies LLC | 80,840 | $162.5K |
| Virtu Financial LLC | 19,982 | $40.0K |
| Kovitz Investment Group Partners, LLC | 19,201 | $38.6K |
| Dimensional Fund Advisors LP | 15,781 | $31.7K |
| Tower Research Capital LLC (TRC) | 1,560 | $3.14K |